Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

HepatologyFurther Publications

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

JAMA Intern Med

Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, Samuel R, Ali B, Desiderio R, Cholankeril G, Bajaj M, El-Serag HB, Asch SM

doi: 10.1001/jamainternmed.2024.4661

Further Publications

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

Am J Gastroenterol

Barritt AS 4th, Tapper EB, Newsome PN, Gazis D, Morris H, Mospan AR, Perez AD, Kim Y, Neuschwander-Tetri BA, Loomba R, Sanyal A, TARGET-NASH Investigators

doi: 10.14309/ajg.0000000000003595

Hepatology

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Gastroenterology

Liu WY, Huang S, Ji H, Kim SU, Cheuk-Fung Yip T, Lai-Hung Wong G, Petta S, Tsochatzis E, Nakajima A, Bugianesi E, George Goh BB, Chan WK, Romero-Gomez M, Sanyal AJ, Boursier J, Hagström H, Calleja JL, de Lédinghen V, Newsome PN, Fan JG, Lai M, Castéra L, Lee HW, Pennisi G, Yoneda M, Armandi A, Kim-Jun Teh K, Gallego-Durán R, Asgharpour A, de Saint-Loup M, Shang Y, Llop E, Fournier C, Mahgoub S, Lara-Romero C, Canivet CM, Sau-Wai Chan M, Lin H, Chen LL, Targher G, Byrne CD, Du M, Wai-Sun Wong V, Zheng MH, VCTE-Prognosis Study Group

doi: 10.1053/j.gastro.2025.02.034

Hepatology

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Am J Gastroenterol

Kim WR, Mannalithara A, Charu V, Chung N, Kwong A, Kwo PY, Torok NJ, Asch SM, Kim SH

doi: 10.14309/ajg.0000000000003268

Hepatology

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

Hepatology

Ng WH, Yeo YH, Kim H, Seki E, Rees J, Ma KS, Moylan CA, Rodriquez LM, Abdelmalek M, Villanueva A, Noureddin M, Yang JD

doi: 10.1097/HEP.0000000000001333

Hepatology

Association of Food Insecurity with the Prevalence and Liver-related Mortality of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

J Hepatol

Younossi ZM, Zelber-Sagi S, Kuglemas C, Lazarus JV, Paik A, de Avila L, Gerber L, Paik JM

doi: 10.1016/j.jhep.2024.08.011

Hepatology

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Lancet Gastroenterol Hepatol

Mikkelsen ACD, Kjærgaard K, Schapira AHV, Mookerjee RP, Thomsen KL

doi: 10.1016/S2468-1253(24)00320-0

Further Publications

Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes

Clin Gastroenterol Hepatol

Faulkner CS, Aboona MB, Surendra L, Rangan P, Ng CH, Huang DQ, Muthiah M, Kim D, Fallon MB, Noureddin M, Chen VL, Kardashian A, Wijarnpreecha K

doi: 10.1016/j.cgh.2024.10.019

Related content

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

Association of Food Insecurity with the Prevalence and Liver-related Mortality of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes